| Autor: |
Elisabetta Antonioli, Sofia Pilerci, Irene Attucci, Gabriele Buda, Alessandro Gozzetti, Veronica Candi, Federico Simonetti, Maria Livia Del Giudice, Sara Ciofini, Michela Staderini, Sara Grammatico, Alessandra Buzzichelli, Maria Messeri, Monica Bocchia, Sara Galimberti, Alessandro M. Vannucchi |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology, Vol 13 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2234-943X |
| DOI: |
10.3389/fonc.2023.1162990 |
| Popis: |
IntroductionCarfilzomib, a potent, irreversible, selective proteasome inhibitor has demonstrated consistent results in relapsed/refractory multiple myeloma (RRMM) combined with lenalidomide and dexamethasone (KRd). No prospective studies are yet available that analyzed the efficacy of the KRd combination.MethodsHerein, we report a multicenter prospective observational study on 85 patients who were treated with KRd combination as the second or third line of treatment, according to standard practice.ResultsThe median age was 61 years; high-risk cytogenetic was found in 26% and renal impairment (estimated glomerular filtration rate (eGFR) |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
